Council of Scientific and Industrial Research

Indian Association for the Cultivation of Science

Arindam Talukdar

Ayan Mukherjee

Biswajit Kundu

Dipyaman Ganguly

Oindrila Rahaman

Swarnali Roy

Barnali Paul

Subhajit Roy

Amrit Raj Ghosh

Roopkatha Bhattacharya

Dipayan Sarkar

Subhendu K Das

Chowdhuri Srijita Paul

Sourav Pal

Shounak Roy

Debomita Bhattacharya

Raychaudhuri Deblina

Benu Brata Das

The invention described herein relates to the compounds of Formula I for treating diseases and disorders for which inhibition or modulation of the topoisomerase I enzyme produces a physiologically beneficial response, in particular for the treatment of breast cancer. Also provided is the process of preparing compounds of Formula I.

Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof

The present invention provides novel purine based compounds of formula 1, method of preparation of purine based compounds and its composition useful for inhibiting signalling through Toll-like receptors. These compounds are useful in inhibiting immune stimulation involving toll-like receptor 9 (TLR9). These can be used in treatment of autoimmune disease and inflammation where aberrant activation of TLR9 plays role. 

Purine based compounds as toll-like receptor 9 antagonist

The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation. 

Blocking toll-like receptor 9 signaling with small molecule antagonist

Growing community of inventors

Kolkata, India

Arindam Talukdar